[go: up one dir, main page]

WO2008131859A3 - Utilisation de dérivés de furopyrimidine à substitution cyclique dans le traitement de l'hypertonie artérielle pulmonaire - Google Patents

Utilisation de dérivés de furopyrimidine à substitution cyclique dans le traitement de l'hypertonie artérielle pulmonaire Download PDF

Info

Publication number
WO2008131859A3
WO2008131859A3 PCT/EP2008/003008 EP2008003008W WO2008131859A3 WO 2008131859 A3 WO2008131859 A3 WO 2008131859A3 EP 2008003008 W EP2008003008 W EP 2008003008W WO 2008131859 A3 WO2008131859 A3 WO 2008131859A3
Authority
WO
WIPO (PCT)
Prior art keywords
pulmonary arterial
hypertonia
treating pulmonary
cyclically substituted
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/003008
Other languages
German (de)
English (en)
Other versions
WO2008131859A2 (fr
Inventor
Thomas Lampe
Eva-Maria Becker
Raimund Kast
Hartmut Beck
Mario Jeske
Joachim Schuhmacher
Friederike Stoll
Martina Klein
Metin Akbaba
Andreas Knorr
Johannes-Peter Stasch
Lars Baerfacker
Alexander Hillisch
Gunter Karig
Mark Meininghaus
Karl-Heinz Schlemmer
Rudolf Schohe-Loop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Priority to CA002685134A priority Critical patent/CA2685134A1/fr
Publication of WO2008131859A2 publication Critical patent/WO2008131859A2/fr
Publication of WO2008131859A3 publication Critical patent/WO2008131859A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de dérivés de furopyrimidine à substitution cyclique de formule (I) dans le traitement et/ou la prophylaxie de l'hypertonie artérielle pulmonaire et d'autres formes de l'hypertonie pulmonaire ainsi que l'utilisation desdits dérivés dans la production de médicaments destinés au traitement et/ou à la prophylaxie de l'hypertonie artérielle pulmonaire et d'autres formes de l'hypertonie pulmonaire.
PCT/EP2008/003008 2007-04-26 2008-04-16 Utilisation de dérivés de furopyrimidine à substitution cyclique dans le traitement de l'hypertonie artérielle pulmonaire Ceased WO2008131859A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002685134A CA2685134A1 (fr) 2007-04-26 2008-04-16 Utilisation de derives de furopyrimidine a substitution cyclique dans le traitement de l'hypertonie arterielle pulmonaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007019690.5 2007-04-26
DE102007019690A DE102007019690A1 (de) 2007-04-26 2007-04-26 Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie

Publications (2)

Publication Number Publication Date
WO2008131859A2 WO2008131859A2 (fr) 2008-11-06
WO2008131859A3 true WO2008131859A3 (fr) 2009-07-16

Family

ID=39777458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/003008 Ceased WO2008131859A2 (fr) 2007-04-26 2008-04-16 Utilisation de dérivés de furopyrimidine à substitution cyclique dans le traitement de l'hypertonie artérielle pulmonaire

Country Status (3)

Country Link
CA (1) CA2685134A1 (fr)
DE (1) DE102007019690A1 (fr)
WO (1) WO2008131859A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
WO2022119823A1 (fr) * 2020-12-04 2022-06-09 The Johns Hopkins University Composés et leur utilisation pour le traitement de la douleur neuropathique

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1817146A1 (de) * 1968-01-05 1969-11-27 Pfizer & Co C 4-Aminofuro[2,3-d]pyrimidine und deren Verwendung als Relaxantien fuer glatte Muskeln
EP1018514A1 (fr) * 1998-07-22 2000-07-12 Suntory Limited INHIBITEURS DE NF-$g(k)B CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF
WO2000075145A1 (fr) * 1999-06-03 2000-12-14 Abbott Laboratories Composes anti-inflammatoires inhibant l'adhesion cellulaire
EP1132093A1 (fr) * 1999-09-17 2001-09-12 Suntory Limited Moyens de prevention ou remedes contre la myocardite, la cardiomyopathie dilatee et l'insuffisance cardiaque contenant des inhibiteurs nf-kappa b en tant qu'ingredient actif
WO2002092603A1 (fr) * 2001-05-14 2002-11-21 Novartis Ag Oxazolopyrimidines et furopyrimidines et utilisation dans des agents pharmaceutiques contre les tumeurs
WO2003022852A2 (fr) * 2001-09-11 2003-03-20 Smithkline Beecham Corporation Composes chimiques
WO2005092896A1 (fr) * 2004-03-12 2005-10-06 Korea Institute Of Science And Technology Compose pour inhiber l'activite tyrosine kinase de la proteine ddr2
WO2005121149A1 (fr) * 2004-06-10 2005-12-22 Xention Discovery Limited Composes de furanopyrimidine efficaces comme inhibiteurs des canaux potassiques
WO2006004658A2 (fr) * 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
WO2007079861A1 (fr) * 2005-12-21 2007-07-19 Bayer Healthcare Ag Nouveaux derives de furopyrimidines a substitution cyclique et leur utilisation pour traiter des maladies cardiovasculaires

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10141212A1 (de) 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
AU2002361992A1 (en) 2001-12-20 2003-07-09 Bayer Aktiengesellschaft 1,4-dihydro-1,4-diphenylpyridine derivatives
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
ES2293077T3 (es) 2002-08-27 2008-03-16 Bayer Healthcare Ag Derivados de dihidropiridinona como inhbidores de hne.
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
EP1539710B1 (fr) 2002-09-10 2010-10-27 Bayer Schering Pharma Aktiengesellschaft Derives heterocycliques
KR20050042190A (ko) 2002-09-10 2005-05-04 바이엘 헬스케어 아게 급성 및 만성 염증성, 허혈성 및 재형성 과정에 대한 치료제로서의 피리미디논 유도체
WO2005080372A1 (fr) 2004-02-19 2005-09-01 Bayer Healthcare Ag Derives de dihydropyridinone
CA2557272C (fr) 2004-02-26 2012-09-11 Bayer Healthcare Ag Derives heterocycliques
US8101615B2 (en) 2004-02-26 2012-01-24 Bayer Pharma Aktiengesellschaft 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1817146A1 (de) * 1968-01-05 1969-11-27 Pfizer & Co C 4-Aminofuro[2,3-d]pyrimidine und deren Verwendung als Relaxantien fuer glatte Muskeln
EP1018514A1 (fr) * 1998-07-22 2000-07-12 Suntory Limited INHIBITEURS DE NF-$g(k)B CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF
WO2000075145A1 (fr) * 1999-06-03 2000-12-14 Abbott Laboratories Composes anti-inflammatoires inhibant l'adhesion cellulaire
EP1132093A1 (fr) * 1999-09-17 2001-09-12 Suntory Limited Moyens de prevention ou remedes contre la myocardite, la cardiomyopathie dilatee et l'insuffisance cardiaque contenant des inhibiteurs nf-kappa b en tant qu'ingredient actif
WO2002092603A1 (fr) * 2001-05-14 2002-11-21 Novartis Ag Oxazolopyrimidines et furopyrimidines et utilisation dans des agents pharmaceutiques contre les tumeurs
WO2003022852A2 (fr) * 2001-09-11 2003-03-20 Smithkline Beecham Corporation Composes chimiques
WO2005092896A1 (fr) * 2004-03-12 2005-10-06 Korea Institute Of Science And Technology Compose pour inhiber l'activite tyrosine kinase de la proteine ddr2
WO2005121149A1 (fr) * 2004-06-10 2005-12-22 Xention Discovery Limited Composes de furanopyrimidine efficaces comme inhibiteurs des canaux potassiques
WO2006004658A2 (fr) * 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
WO2007079861A1 (fr) * 2005-12-21 2007-07-19 Bayer Healthcare Ag Nouveaux derives de furopyrimidines a substitution cyclique et leur utilisation pour traiter des maladies cardiovasculaires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 2002 (2002-11-01), GALIÈ NAZZARENO ET AL: "Emerging medical therapies for pulmonary arterial hypertension.", XP002528176, Database accession no. NLM12525997 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 2006 (2006-09-01), BRESSER PAUL ET AL: "Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.", XP002528177, Database accession no. NLM16963540 *
PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY SEP 2006, vol. 3, no. 7, September 2006 (2006-09-01), pages 594 - 600, ISSN: 1546-3222 *
PROGRESS IN CARDIOVASCULAR DISEASES 2002 NOV-DEC, vol. 45, no. 3, November 2002 (2002-11-01), pages 213 - 224, ISSN: 0033-0620 *

Also Published As

Publication number Publication date
CA2685134A1 (fr) 2008-11-06
DE102007019690A1 (de) 2008-10-30
WO2008131859A2 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
MX2010006033A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso.
TN2009000132A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
WO2010057101A3 (fr) Composés utiles en tant qu’inhibiteurs de vih
WO2009026179A3 (fr) Composés de proanthocyanidine anti-infectieux et leurs procédés d'utilisation
WO2007125105A3 (fr) Activateurs de la glucokinase benzamidique
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
MY150702A (en) Substituted 4-phenyltetrahydroisoquinonelines, method of producing them, their use as medicament, and also medicament containing them
WO2009074247A8 (fr) Nouveaux dérivés d'amide d'acide 2-arylthiazole-4-carboxylique, leur préparation et leur utilisation en tant que médicament
TW200621765A (en) Substituted phenylaminothiazoles and their use
MY150931A (en) Substituted oxazolidinones and their use
WO2006072458A3 (fr) Derives d'oxindol substitues, agents pharmaceutiques les contenant, et leur utilisation
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
MX2007012538A (es) Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias.
NO20083901L (no) Fiksert-dose-assosiasjon av fytat og sink
MX2010002007A (es) Sulfonas ciclicas sustituidas por amino-bencilo utiles como inhibidores de bace.
WO2008046407A3 (fr) Utilisation de dioxyde de deutérium pour traiter des maladies hyperprolifératives de la peau
DOP2006000062A (es) Derivados de acido pirimidincarboxilico y su uso
WO2008131859A3 (fr) Utilisation de dérivés de furopyrimidine à substitution cyclique dans le traitement de l'hypertonie artérielle pulmonaire
ATE380188T1 (de) Substituierte chinolone
UA94080C2 (ru) Ациклически-замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний
WO2006023843A3 (fr) Nouveaux hétérocycles
WO2006089664A3 (fr) Imidazoles substitues par heterocyclylamide
WO2010107791A3 (fr) Composés de pyrazinoisoquinoline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08735263

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008735263

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2685134

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010504502

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP